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Abstract
Background: For many women finding the right contraceptive method can be challenging and consistent
and correct use over a lifetime is difficult. Even remembering to take a birth control pill every day can be
a challenge. The primary objective of this study was to evaluate women's experience with a weekly
ethinylestradiol/norelgestromin contraceptive patch (EE/NGMN patch), given new technologies recently
developed in hormonal contraception to increase women's options in avoiding daily dosing.
Methods: In 24 Italian sites, 207 women received the EE/NGMN patch for up to 6 cycles. At study end,
overall satisfaction and preference, as well as compliance, efficacy and safety, were evaluated.
Results: 175 women (84.5%) completed the study. The overall satisfaction rate was 88%; convenience and
once-a-week frequency of the patch were especially appreciated. At baseline, 82 women (39.4%) were
using a contraceptive method, mainly oral contraceptives and barrier methods, but only 45.1% were very
satisfied/satisfied; after 6 months with the patch, 86.3% of this subset was very satisfied/satisfied.
Considering the method used in the 3 months before the study entry, 78.1% strongly preferred/preferred
the patch, for convenience (53.9%), ease of use/simplicity (28.9%), fewer (9.2%) and less severe (2.6%) side
effects. Compliance was very high: 1034/1110 cycles (93.2%) were completed with perfect compliance and
the mean subject's compliance score was 90%. One on-therapy pregnancy occurred. The patch was safe
and well tolerated: adverse events frequency was low, with predominantly single reports of each event.
Most of them started and subsided during cycle 1.
Conclusion: This study demonstrated that the EE/NGMN patch is associated with high satisfaction levels
and excellent compliance. At study end, the majority of women indicated that they would continue using
the patch.
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Background
Combined oral contraceptives are one of the most effec-
tive and commonly used forms of reversible contracep-
tion, used by more than 100 million women worldwide
for family planning [1,2]. If taken exactly according to the
provided instructions (perfect use), oral contraceptives are
almost 100% reliable, with a failure rate of 0.1 per 100
women in the first year of use [2]; in clinical practice (typ-
ical use), the failure rate can be up to 5 per 100 women
years [2], mainly due to non-compliance or imperfect
compliance with the once daily regimen [3-5]. For this
reason, a new technology with comparable contraceptive
efficacy and safety, but not requiring daily compliance,
was developed [6].
The application of transdermal technology to a birth con-
trol product was considered a milestone in transdermal
drug delivery development and the ethinylestradiol/nore-
lgestromin patch (EE/NGMN patch) was the first and
unique contraceptive patch to receive worldwide regula-
tory approval [7]. The EE/NGMN patch marketed in
Europe is a three layer 20 cm2 patch containing ethi-
nylestradiol 0.6 mg and norelgestromin 6.0 mg, applied
once weekly for 3 consecutive weeks followed by a patch-
free week [8]. During the 7-day wear period, the patch
continuously delivers ethinylestradiol and nore-
lgestromin, thereby avoiding peaks and troughs seen with
oral contraceptives [9]. The steady-state concentrations
are reached after about 48 hours. There are fewer conse-
quences of dosing errors with the patch than with oral
contraceptives: even if a scheduled patch change is
delayed for 2 days during weeks 2 and 3, clinical efficacy
is maintained, and backup contraception is not needed
[10].
The synthetic progestin norelgestromin (17-deacetyl
norgestimate, active metabolite of norgestimate) was cho-
sen for the patch [8]. Both norgestimate and nore-
lgestromin, virtually equivalent from metabolic and
endocrine perspectives, have a low androgenicity due to
their negligible binding affinities for the androgen recep-
tor and for the sex hormone-binding globulin (SHBG)
[11,12]. A clinical study showed that the patch had an
effect comparable to the norgestimate-containing oral
contraceptives on several key androgenic markers, sug-
gesting this patch containing norelgestromin may
improve disorders resulting from androgen excess [13]. In
vitro studies demonstrated that norgestimate is a strong
inhibitor of 5α-reductase (responsible for transforming
testosterone to more potent dihydrotestosterone) in the
skin [8,14]; in addition, the antiandrogenic activity of
these progestins has been recently confirmed in an in vitro
study where norgestimate and norelgestromin activity was
50% that of cyproterone acetate [15].
Several clinical studies showed that the clinical efficacy of
the contraceptive patch in preventing unintended preg-
nancy is similar to that of oral contraceptives, with the
benefit of once-weekly administration [16,17]; in a
pooled analysis of three Phase III studies (3.319 women,
22.160 treatment cycles), the overall annual probability
of pregnancy was 0.8% and the method failure probabil-
ity was 0.6%, without differences across age [18]. The fol-
licular size and the incidence of ovulation were
significantly reduced in contraceptive patch users com-
pared with oral contraceptive users, both in normal cycles
and after planned dosing errors [19].
A pooled analysis of the same three Phase III studies pre-
viously mentioned, but limited to the subset of North
America centers (1.785 women, 11.772 treatment cycles),
showed that compliance (adherence to the regimen or
perfect use) with the contraceptive patch was remarkably
good: the rate of cycles with perfect use of the patch
ranged within age groups from 88.1% to 91.0%, and
adherence to the weekly schedule was significantly better
than with daily oral contraceptives (p < 0.001), especially
in younger women (< 20 years: 67.7% vs 87.8%) [20-22].
Another pooled analysis of the same three Phase III stud-
ies, integrated by 30 women from a three-period crossover
exercise study (3.349 women, 70.639 patches worn),
showed that the reliability of adhesion of the contracep-
tive patch was excellent and consistent across all studies
[23]. Heat, humidity and exercise did not affect adhesion
[23].
Finally, the adverse effect profile of the contraceptive
patch is similar to that of oral contraceptives (most fre-
quent adverse events: headache and nausea), with the
exception of a higher incidence of application site reac-
tions, breast discomfort and dysmenorrhoea in the patch
group, most of them mild or moderate in severity [24].
Recent epidemiologic case-control studies conducted in
the United States reported that the risk (i.e., odds ratio
OR) of venous thromboembolism with the contraceptive
patch compared to that of oral contraceptives containing
ethinylestradiol 35 μg and norgestimate or ethinylestra-
diol 30 μg and levonorgestrel ranged from 0.9 (indicating
no increase in risk, 95% CI 0.5–1.6) to 2.4 (indicating an
approximate doubling of risk, 95% CI 1.1–5.5) [25-29].
However, in the contraceptive setting, other factors
beyond efficacy and safety of the method (i.e. simplicity
and ease of use, women's acceptability, satisfaction, addi-
tional benefits) can influence women's choice, adherence
and persistence of use. In general, nearly half of contra-
ception users are not completely satisfied with their cur-
rent method: actual or expected side effects, difficulty of
use, worry about effectiveness and reduced sexual pleas-
ure are just some of the many reasons women give forBMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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being dissatisfied. Obviously, women who are not com-
pletely satisfied are more likely than satisfied users to
make mistakes (e.g. gap in use, incorrect or inconsistent
use) and to discontinue the method, putting themselves at
high risk of unintended pregnancy [3]. So, contraceptive
success and long-term adherence is strongly related to the
subject's satisfaction [3].
In order to investigate women's experience with the EE/
NGMN patch, a pan-European study, named "EVRA Con-
trast" (NRGEEP-CON-402), was carried out [30,31]. The
primary objective of the study was to evaluate, specifi-
cally, user satisfaction and, if applicable, user preference
in comparison with the previous contraceptive method.
The secondary objectives were to monitor contraceptive
efficacy, safety, and user compliance with the transdermal
patch. Italy took part in this study, but with different time-
lines compared to other countries, because Italian Investi-
gators added an additional sub-study to assess body
composition with bioelectrical impedance analysis (BIA).
Italian data regarding women's experience with the patch
are now presented in this paper.
Methods
Study design and visits
In Italy, this open-label, single-arm multicentre study was
conducted in 24 sites, between June 2004 and November
2005, in accordance with the principles of the Interna-
tional Conference on Harmonization (ICH) Good Clini-
cal Practice (GCP) and the latest revision of the
Declaration of Helsinki; ethics approval was obtained in
writing by the Independent Ethics Committees (IECs) of
each study centre. After informed consent signature, study
participants were scheduled to receive the EE/NGMN con-
traceptive transdermal patch (EVRA, Janssen-Cilag Inter-
national N.V., Belgium) for 24 weeks (6 cycles of 4
weeks).
A screening visit (Visit 1: eligibility, informed consent,
medical and gynaecological history, vital signs, weight
and height, subject satisfaction with the current method
of contraception if any, overall health status through the
validate questionnaire SF-12® Health Survey [32,33], preg-
nancy test), followed by visits after cycle 1 (Visit 2), cycle
3 (Visit 3), and cycle 6 (Visit 4) of treatment were sched-
uled. Pregnancy test was done in V1 and repeated at the
end of study (Visit 4, or early withdrawal), or earlier if
pregnancy was suspected (missed withdrawal bleeding).
At Visits 3 and 4, each subject was asked to complete a set
of questions concerning her satisfaction with the contra-
ceptive patch, as well as questions about her overall health
status, incorporating the SF-12® Health Survey. Adverse
events, concomitant medications and body weight were
recorded throughout the study. A further contact (tele-
phone or visit) was also performed between Visit 1 and 2
to confirm subject's start of menses and of study medica-
tion. Due to a local amendment, at each visit, Italian
Investigators assessed women's body composition with
bioelectrical impedance analysis: these results have been
recently published in a nutrition journal [34].
Participants
Healthy women aged 18 to 45 years, sexually active and at
risk of pregnancy, having a regular menstrual cycle occur-
ring every 25–35 days (except for women using an
implant), not pregnant, with a normal Pap smear within
the previous 12 months, agreeing to use only the assigned
study drug as contraception during the study (except
when back-up contraception was required for sexual
transmitted disease protection, detached or delayed patch
changes) and having signed the Informed Consent Form
were eligible to participate in the study. Participants were
excluded in cases of: known history or presence of con-
traindications to hormonal contraceptives; recent history
of alcohol or other substance abuse; oily, irritated or dam-
aged skin at all potential sites of application; chronic use
of barbiturates, anti-epileptics, rifampin, griseofulvin, or
other hepatic enzyme-inducing drugs or of systemic anti-
biotics; concurrent use of an oestrogen and/or progestin-
containing medication; any experimental drug and/or
experimental device within 30 days prior to the screening
visit.
Study medication
Eligible subjects applied the first patch on the first day of
menses (immediately after removal of an implant, 12
weeks-12 weeks and 5 days following the last DMPA injec-
tion) for 1 week and replaced on the same day of the week
for 3 consecutive weeks. The application sites were but-
tocks, abdomen, upper torso or upper outer arm (exclud-
ing breasts), using each time a different place to avoid
potential irritation. If the patch partly or completely
detached for < 24 hours, the patch was to be re-applied to
the same place or replaced with a new patch immediately
without additional contraception; for > 24 hours or if the
subject was not aware when the patch had lifted or
become detached, the subject started a new cycle of 3
weeks, using a non-hormonal back-up method for the
first 7 days.
Study evaluation
Subject satisfaction after 3 and 6 cycles of patch use was
assessed by the Measures of Satisfaction, General Health
and Wellbeing questionnaire, including the SF-12® Health
Survey. The Investigator gave a paper questionnaire, trans-
lated in local language, to each woman and she filled in it
during the visit. When applicable, a comparison was
made between the patch and the method used at study
entry. The subject's post-study contraceptive choice was
also recorded. Compliance was assessed at all visits byBMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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inspection of returned study medication boxes and review
of Diary Cards. Conflicting information between the two
sources of data were analysed, discussed with the woman
and then fixed by the Investigator during each visit; if nec-
essary corrections to Diary Cards were made under the
supervision of the Investigator. Adherence was calculated
using the verified data from Diary Cards. A perfect compli-
ance cycle was defined as 21 consecutive days of patch use
with no patch worn longer than 7 days and the patch-free
interval minimally 1 and maximally 7 days. A subject
compliant score (%) was calculated as number perfect
compliant cycles/number ITT cycles per each participant
(ITT cycles defined as all the cycles of the ITT population,
i.e. women who used at least 1 study patch during the
trial, regardless of whether the patch was used at all during
the cycle).
The Pearl Index (number of pregnancies per 100 woman-
years of product use) and life table analysis (gross cumu-
lative probability of pregnancy) were used to assess con-
traceptive efficacy. Adverse events were reported and
recorded from the time of the first study-related procedure
to the time of the last study-related procedure.
Statistical analysis
In Italy about 200 subjects were planned to enter the
study. As defined by the study protocol, all subjects who
used at least 1 study patch were considered enrolled and
included in the analyses (ITT population). Categorical
data (medical and gynaecological history, primary contra-
ceptive information, concomitant medications) were
summarized by subject counts and percentages, and con-
tinuous variables (e.g., age, weight, scores, vital signs,
BMI) by the means, medians, standard deviations,
maxima, minima and numbers of subjects, as appropri-
ate. The number and percentage of subjects in each age
class (i.e., ≤ 21, 22–25, 26- ≤ 30, 31- ≤ 40, 41- ≤ 50, >50)
were tabulated. Differences of continuous and ordinal
variables (satisfaction degree, quality of life questionnaire
SF-12®, personal preference, future contraceptive use,
application site and patch removal, compliance) were
analyzed within group with the Wilcoxon signed rank test,
and between groups with the Wilcoxon two-sample test.
Between groups differences of categorical variables were
tested by means of the Fisher exact test. Statistical signifi-
cance was declared at the 5% level (2-sided).
The Pearl Index (determined from the number of on-ther-
apy pregnancies multiplied by 1300, divided by the
number of cycles on therapy) was calculated for the ITT
subset and for the Perfect Compliance subset of subjects.
A 95% confidence interval of the Pearl index was calcu-
lated using the Poisson method. Cumulative pregnancy
rates were calculated by the Kaplan-Meier method. The
number and percentage of subjects with at least one
adverse event were tabulated. Tables of the type and inci-
dence of adverse events were presented using the WHO
system organ class.
Results
Demographic and baseline characteristics
Two hundred and seventeen women were screened in
Italy; 207 used at least one patch, they were considered
enrolled and they were included in the analyses (ITT pop-
ulation). Because all subjects (207 women) provided
diary data and had (minimally) 1 follow up visit, the end-
point could be calculated for all subjects. 175 women
(84.5%) completed the 6-month study; of the 32 drop-
outs (47% of whom discontinuing after Cycle 1), 11 with-
drew because of adverse events, 10 for subject's choice, 4
were lost to follow-up, 1 became pregnant and 6 for other
reasons. Considering the discontinuation rate by cycle, 15
women discontinued the study after cycle 1, 8 women
after cycle 2, 7 women after cycle 3 and 2 women after
cycle 4. In summary, V1, V2 and diary data are available
for 207 women who used at least one patch, as well as V3
data for 189 women and V4 for 177 women; finally, 175
women completed the 6-cycle study.
The subjects' baseline characteristics are summarized in
Table 1. The mean age of the women was 28.4 (SD 6.4)
years, divided into the following age classes: 31 to 40
years: 30.4%; 26 to 30 years: 29.5%; 22 to 25 years:
18.8%; 18 to 21 years: 16.9% and 41 to 45 years: 4.4%.
About 79% of the women had a BMI class of 18.5 to 25
kg/m2 and only 5 subjects had a BMI above or equal to 30
kg/m2. Sixty-one subjects (29.5%) smoked an average of
8.4 (SD 6.3) cigarettes per day.
At screening visit, 18% of the subjects reported one or
more currently active concomitant morbidities, mainly
involving the allergic/immunologic (10%), the gastroin-
testinal (3%), the endocrine (2%), the dermatological
(2%) and the genito-urinary (2%) system. One hundred
and twenty-nine subjects (62.3%) were nulligravida, 143
(69.1%) were nullipara (Table 1) and the mean numbers
of pregnancies and deliveries were 0.7 and 0.5, respec-
tively.
Overall, 98/207 subjects (47.3%) had used a contracep-
tive method in the 3 months prior to study entry: oral con-
traceptives (45 women, 21.7%), barrier methods (43
women, 20.8%), other methods (10 subjects, 4.8%).
At study entry, 82 women (39.6%) were still using a con-
traceptive method (Table 1). Using a five point scale ques-
tionnaire, these subjects expressed their opinion regarding
convenience, inconsistent use, worry about getting preg-
nant, incorporation into their lifestyle, frequency of use,
feeling secure, improvement of sex life, acceptance byBMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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their partner and overall satisfaction. Only 30.5% of
women judged their method as convenient, 39% of them
never forgot it and 68.3% was never or minimally worried
about getting pregnant despite the method; 50 women
(60.9%) agreed on the easy incorporation of the method
into their lifestyle and 33 (40.2%) were satisfied with the
frequency of method use. In 67.1% of cases women felt
confident about the security of the method, but only in
about one third of the cases the used method improved
their sexual life. Overall, 45.1% of the subjects were very
satisfied/satisfied, while 26.9% of them were very dissatis-
fied/dissatisfied with their current contraceptive method
(Table 1).
Compliance
Of the 1110 ITT cycles, 1034 (93.2%) were perfectly com-
pliant. The mean subject compliant score was 90%. 134/
175 (76.6%) subjects had 6 cycles perfectly compliant.
Buttocks (50.8%) and abdomen (30.6%) were the most
used application sites. One hundred and fifty-nine sub-
jects changed the application site at least once during the
study; the most common reasons for patch removal was a
Table 1: Baseline subjects' characteristics (N = 207)
DEMOGRAPHIC CHARACTERISTICS Mean ± SD
Age, years 28.4 ± 6.4 (range 18 – 45)
Weight, Kg 57.9 ± 8.8 (range 42 – 110)
Height, cm 163.2 ± 6.1 (range 147 – 180)
Body Mass Index, Kg/m2 21.8 ± 3.1 (range 15 – 38)
Pulse, beats per minute 72.4 ± 6.7 (range 54 – 91)
Systolic blood pressure, mmHg 112.8 ± 9.6 (range 80 – 140)
Diastolic blood pressure, mmHg 70.7 ± 7.0 (range 58 – 85)
Smokers (n, %) 61 (29.5)
OBSTETRIC AND GYNAECOLOGICAL HISTORY Mean ± SD
Cycle length, days 28.6 ± 1.7 (range 25 – 35)
Period length, days 4.7 ± 1.1 (range 2 – 8)
Pregnancies (n, %) Deliveries (n, %) Women (n, %) Women (n, %)
0 0 129 (62.3) 143 (69.1)
1 1 31 (15.0) 29 (14.0)
2 2 28 (13.5) 29 (14.0)
3 3 12 (5.8) 6 (2.9)
44 7  ( 3 . 4 ) -
Contraceptive methods currently used at baseline (n, %) Women (n, %)
None 125 (60.4)
Oral contraceptive 37 (17.9)
Vaginal ring 2 (1)
Intrauterine method 1 (0.5)
Withdrawal method 3 (1.4)
Natural family planning method 1 (0.5)
Barrier method 35 (16.9)
Not reported 3 (1.4)
Degree of satisfaction with the contraceptive methods currently used at baseline (n = 82, %) Women (%)
Very satisfied 6.1
Satisfied 39.0
Neither satisfied nor dissatisfied 28.0
Dissatisfied 23.2
Very dissatisfied 3.7BMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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scheduled change (92%), partial detachment (4.2%),
complete detachment (3%), skin reaction (0.3%).
Satisfaction
At Visits 3 and 4, a satisfaction questionnaire was filled in:
the results are summarized in Table 2. Overall, the major-
ity of the subjects responded favourably about all the
aspects. At the end of the last cycle, almost 90% consid-
ered the transdermal contraception very convenient/con-
venient, 96% appreciated once-a-week frequency and
95% reported they easily incorporated the patch into life-
style. The scores at Visit 4 did not differ statistically signif-
icantly from the Visit 3 scores, except for the satisfaction
with the frequency of application, which increased from
Visit 3 to Visit 4 (p < 0.01). Concerning satisfaction versus
the baseline method, the rate of subjects very satisfied or
satisfied with their contraceptive method increased from
45.1% at baseline to 82.9% at Visit 3 and 86.3% at Visit 4
(Figure 1).
Preference, Quality of Life and future contraception
Comparing the transdermal patch with the primary con-
traceptive method used in the 3 months before, 68/87
subjects (78.1%) had a preference or strong preference for
the patch (Figure 2); the main reasons for this choice were
convenience (53.9%), ease of use/simplicity (28.9%) and
fewer or less severe side effects (11.8%). 30 subjects
(75%) who used oral contraceptives and 34 subjects
(87.2%) previously using barrier methods as their pri-
mary method of contraception in the previous 3 months,
had a preference or strong preference for the patch. Over-
all, the percentage of subjects with preference for the
patch was greater for subjects that completed the study
(66/81, 81.5%) than for those who did not, though infor-
mation about their preference was available only for 6
non-completers, 2 of them had a preference for the patch.
The indication of preference for the transdermal patch was
consistent with the satisfaction score.
Quality of Life Questionnaire SF-12 included Physical
Component Summary (PCS) and Mental Component
Summary (MCS) evaluation. The mean PCS value was sta-
ble during the study visits, although the mean MCS was
statistically higher at Visits 3 and 4, and at endpoint than
at baseline (p < 0.001, p = 0.0049, and p < 0.05, respec-
tively).
When questioned about their future contraceptive use,
114 out of 201 subjects (56.7%) specified that they would
use the transdermal patch, 46 (22.9%) did not intend to
use any contraceptive method and only 19 subjects
(9.5%) would prefer to use an oral contraceptive. Almost
all subjects who would use the patch as their future con-
traceptive method completed the study (111/114; 97%).
Efficacy
Contraceptive efficacy was assessed for all the participants
who used at least 1 study patch. One on-therapy preg-
nancy occurred during the study, presented as a pregnancy
due to "method failure" because, from the subject's Diary
Cards, there was no 100% certainty that the patch was
replaced more than 24 hours after a detachment (perfect
compliance demanded that a detached patch should be
replaced within 24 hours; just in case of proved inconsist-
ent use a pregnancy can be considered "user failure"). Glo-
bally, the Pearl Index for the ITT population, based on
1110 cycles, was 1.17, 95% CI (-1.12, 3.47); the Pearl
Index for the Perfect Compliance subset, based on 1034
cycles, was 1.26, 95% CI (-1.21, 3.72). Kaplan Meier esti-
mates of the cumulative probabilities of pregnancy were
determined to be 0.57% for the ITT subset and 0.60% for
the Perfect Compliance subset, respectively.
Safety
Overall, the subject's mean pulse, systolic and diastolic
blood pressure did not change significantly during the
study. The mean increase in body weight from baseline to
Visit 4 was minimal (0.7 kg), while the mean BMI
increased by 0.3 kg/m2. These increases were statistically
significant (p < 0.0001), but were not considered clini-
cally relevant.
Seventy-one subjects (34.3%) experienced one or more
adverse events during the 24 weeks of treatment. The most
frequently reported adverse events are summarized in
Table 3. About 93% of adverse events were mild (63.9%)
or moderate (29.2%) in severity, with only 6.9% judged
as severe. In 28.5% of cases no correlation to the study
medication was found and only 13.2% of the events were
considered very likely related to the patch. No serious
adverse events or deaths occurred during the study period.
Comparison between satisfaction with the contraceptive  patch and with other methods used at baseline Figure 1
Comparison between satisfaction with the contra-
ceptive patch and with other methods used at base-
line.BMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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Table 2: Subjects' responses to questions about satisfaction with the contraceptive patch
Response Visit 3
(3 months)
N (%)a
Visit 4
(6 months)
N (%)b
Patch was convenient/very convenient 163 (81%) 155 (88%)
Worried a little/none of the time about getting pregnant 173 (86%) 155 (88%)
Satisfied/very satisfied about adhesion of patch 159 (79%) 150 (85%)
Satisfied/very satisfied about adhesion of patch in heat/humidity 138 (68%) 127 (72%)
Satisfied/very satisfied with choice of 4 application sites 161 (80%) 148 (84%)
Agreed/strongly agreed easily incorporated patch into lifestyle 177 (88%) 169 (95%)
Agreed/strongly agreed satisfied with once-a-week frequency 184 (91%)* 169 (96%)*
Agreed/strongly agreed felt secure that patch works 165 (82%) 158 (89%)
Agreed/strongly agreed patch improved sex life 101 (50%) 102 (58%)
Agreed/strongly agreed partner accepted patch 152 (75%) 140 (79%)
Overall satisfaction with the patch 167 (83%) 156 (88%)
a On a total of 202 subjects
b On a total of 177 subjects
*P < 0.01 V4 vs V3
Treatment preference at study end (A) and reasons for contraceptive patch preference (B) Figure 2
Treatment preference at study end (A) and reasons for contraceptive patch preference (B).
 
A B 3,4
6,9
11,6
42,5
35,6
Strong preference previous method
Preference previous method
No preference
Preference patch
Strong preference patch
 
53,9
28,9
9,2
2,6
5,4
Convenience Easy use/simplicity
Fewer side effects Less severe side effects
OtherBMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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Overall, only 11 women (5,3%) withdrew from the study
because of adverse events due to localized skin reactions
(3 cases), headache (2 cases, one of which associated with
vomiting), allergy, anxiety with nausea and rash, breast
pain, itching, decreased libido and spotting between men-
ses (1 case each).
The frequency of adverse events was higher during the first
cycle: 49.3% of adverse events started during the first cycle
of the study, but 34% of them stopped during the same
cycle. It is noteworthy that the frequency decreased over
time; in fact, only 20% of emergent adverse events started
after third cycle. The most prevalent adverse events in
cycle 1 were headache (4%) and spotting between menses
(3%), and by cycle 4 their prevalence decreased to 1% and
0%, respectively (Figure 3).
Discussion
The primary objective of this multicentre study was to
evaluate satisfaction, preference, compliance and well-
being following use of the contraceptive patch, in a natu-
ralistic setting as close to the real-life situation as possible
("real world" use), in order to have data reflecting how the
patch is normally used by European/Italian women.
In Italy, after 6 cycles of patch treatment, the satisfaction
rate in all women was 88%; considering only the women
using a contraceptive method at baseline, their satisfac-
tion increased from 45% with the previous method to
86,3% with the patch while the dissatisfaction decreased,
respectively, from 27% to 4%. This is in agreement with
other studies with the contraceptive patch: Wan reported
significantly higher levels of satisfaction in the women
who used the contraceptive patch compared to the oral
Table 3: Most commonly adverse events occurred during the 
study period (> 2% of the subjects)
Adverse events N % of women
Headache 21 10.1
Spotting between menses 9 4.3
Itching 7 3.4
Nausea 6 2.9
Breast pain 6 2.9
Localised skin reaction 6 2.9
Breast tension 5 2.4
Prevalence in each cycle of the most frequently mentioned adverse events (> 2% of the subjects) Figure 3
Prevalence in each cycle of the most frequently mentioned adverse events (> 2% of the subjects).BMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
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contraceptive users (OR = 2.05; p = 0.001) [35], while
Weisberg showed that out of 279 participants who com-
pleted 9 cycles, 91% were satisfied with the patch [36]. In
an international randomized trial conducted on 1489
women, significantly more users were very satisfied with
the contraceptive patch compared to oral contraceptives
(p > 0.05) and, in contrast to oral contraceptives, the per-
centage of women being very satisfied with the patch,
gradually increased with age, resulting in a more pro-
nounced difference in women aged > 34 [37]. Finally,
97% of adolescents evaluated in a recent study were very
satisfied/somewhat satisfied with the contraceptive patch
and 93% of them stated that they would recommend it to
a friend/relative [22].
Concerning the comparison with the method used in the
3 months before study enrolment, 78.1% of subjects had
a preference/strong preference for the patch due to con-
venience, ease of use/simplicity and fewer side effects of
the patch over the other methods; similarly, Weisberg
reported that almost 3 out of 4 participants preferred the
patch to their previous method [36]. In this regard, 93%
of adolescents reported that they remembered to apply
the patches on time, and 40% of them stated that its use
was easier than that of previous contraceptive methods
[22].
The high level of satisfaction and preference with
transdermal contraception may be considered important
when trying to maximize long-term compliance. In this
study, compliance was very high (93,2% perfectly dosing
cycles), in accordance with the pooled analysis of rand-
omized controlled trials (88.7% vs 79.2% of oral contra-
ceptives, p < 0.001). In the observational study conducted
in Canada, patch perfect compliance was high across all
cycles (88%) and did not differ significantly across age
[36]. Similarly, Urdl demonstrated that compliance was
consistently better in the patch group (range 90 to 97%)
compared to the oral contraceptive group (85 to 92%)
[37]. The once-weekly application schedule for the patch
is desirable because it is well suited to the lifestyle of Euro-
pean women, including younger women for whom com-
pliance with oral contraceptives is a particular issue
[20,37].
The improved compliance observed with the patch may
lead to fewer unintended pregnancies [8,16,21], although
confirmation of this would require additional clinical
studies. Only 1 pregnancy was reported and occurred dur-
ing the study (confirmed by urine and blood positive
pregnancy tests, gynaecological examination and ultra-
sound). These data are consistent either with those of the
pooled analysis [18] or with the more recent multicentre
studies, evaluating a high number of women in condi-
tions very close to real use in daily life [36,37].
In this study, the reporting frequency for each adverse
event was lower than rates for the same adverse events
reported in other clinical trials. Headache was the most
frequently reported event, followed by spotting between
menses, itching, breast pain, localized skin reaction, nau-
sea, and breast tension. In our study, application-site reac-
tions (2.9%) were significantly lower than the 17.4% in
the phase III studies pooled analysis [24] and the 13.8%
reported by Urdl [37]. According to Weisberg, application
site reaction was the most common patch-related adverse
event in cycle 1, but diminished greatly in the successive
cycles [36]. In general, < 2% of participants discontinued
patch treatment for this reason [24,37].
Severity of the events, withdrawal due to safety and
improvement of tolerability with progressive cycles were
consistent with, or better than, those seen in previous
studies [24,36,37]. In aggregate, these safety data indicate
that the patch is well tolerated, with an adverse event pro-
file similar to oral contraceptives [24,37].
The main strength of our findings is the fact that this is the
first multicentre Italian study specifically designed to eval-
uate women's satisfaction and preference with the contra-
ceptive patch in comparison to the previous methods.
Even if several trials evaluated these items in Europe (but
not in Italy) and in South Africa [37], in the United States
[35] and in Canada [36], our data are the first published
regarding Italian women. The open study design with
broad selection criteria enabled data to be gathered on the
patch in everyday woman use, with the minimum of inter-
ventions, and the results reflected how the contraceptive
patch is normally used in Italy. These results can be con-
sidered innovative if we take into account that the choice
and the preference for a contraceptive method could be
different from country to country and influenced by dif-
ferent factors such as cultural and religious ones.
However, our study has also several limitations. Firstly,
this is a non-randomized observational trial. This kind of
approach can introduce bias, because a subject could be
unconsciously predisposed to favour the new therapeutic
option. But, in this study, only 50% of participants
adopted a contraceptive method in the 3 months before
enrolment, and the degree of satisfaction at study end was
very high in all the subjects. In addition, an open-label,
single arm design was chosen to reflect how women under
"real world" circumstances normally use the contraceptive
patch. Secondly, the characteristics of women who per-
fectly adhere to the regimen, as well the possible factors
associated with the women who were very satisfied/satis-
fied with the patch, were not investigated in details; how-
ever, considering the relatively small number of our
population (207 women, 175 of them are completers), we
think that this type of analysis (e.g. analysis per ageBMC Women's Health 2009, 9:18 http://www.biomedcentral.com/1472-6874/9/18
Page 10 of 11
(page number not for citation purposes)
classes, per number of previous pregnancies/deliveries)
could not be feasible and/or significant from a statistical
point of view. Thirdly, women could use condoms during
the study and a monogamous relationship without the
need for STI protection was not an eligibility requirement.
This strict lifestyle criterion was not adopted because the
objective of this study was to evaluate the real-life use of
the patch and not to collect information on a restricted
population of women (observational study, without any
registration purpose). For this reason, information about
condom use, as well as the number of intercourses by
cycle, were not collected. Finally, because all of the
women agreed to use the patch, the adherence and accept-
ability results might not be representative of the general
population, with a possible over-estimation of the satis-
faction and adherence. By contrast, also in this case, the
study reflects real-life situation: in clinical practice,
woman are usually used to discussing the choice of a con-
traceptive method with their own Gynaecologist/GP, and
this mutual decision making with her doctor is very
important to reach a "therapeutic alliance", valuable pre-
dictor of patient's adherence and persistence.
Conclusion
In addition to clinical efficacy in preventing unintended
pregnancies, the choice of a contraceptive method should
take into account other important attributes of the treat-
ment that impact on compliance, such as women's prefer-
ence, satisfaction, well-being and ease of use. Specifically,
satisfaction with the contraceptive method is essential for
long-term adherence because human behaviour tends to
be repeated when it is rewarding (e.g. when the method
satisfies the personal needs of the woman and her part-
ner). In this sense, transdermal contraception has pro-
vided an important new option for many women. The EE/
NGMN contraceptive patch is as effective and well toler-
ated as oral contraceptives; the convenience and simplic-
ity of a weekly change schedule for the patch may
contribute to its high degree of satisfaction. In conclusion,
high satisfaction levels, coupled with excellent compli-
ance, make the contraceptive patch a reasonable option
for women desiring hormonal contraception.
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